Certified Health IT Transparency and Disclosure Information 2014 Edition

Transcription

1 Certified Health IT Transparency and Disclosure Information 2014 Edition

2 2015 Edition Certified Health IT Transparency and Disclosure Information I. Disclaimer This Complete EHR is 2014 Edition compliant to the criteria listed below and has been certified by an ONC Accredited Certifying Body in accordance with the applicable certification criteria adopted by the Secretary of Health and Human Services. This certification does not represent an endorsement by the U.S. Department of Health and Human Services. II. Certified EHR Vendor & Product Information Vendor/Developer Name: Certified EHR Name: Practice Type: Previous Certified Version Numbers (CHPL Certification ID): athenahealth, Inc. athenaclinicals Ambulatory 14.4 (Cert ID: R00) 14.5 (Cert ID: R01) 14.6 (Cert ID: R02) 14.7 (Cert ID: R03) 14.8 (Cert ID: R04) 14.9 (Cert ID: R05) (Cert ID: R06) (Cert ID: R07) (Cert ID: R08) 15.1 (Cert ID: R09) 15.2 (Cert ID: R00) 15.3 (Cert ID: R01) 15.4 (Cert ID: R02) 15.5 (Cert ID: R03) 15.6 (Cert ID: R04) 15.7 (Cert ID: R05) 15.8 (Cert ID: R06) 15.9 (Cert ID: R07) (Cert ID: R08) (Cert ID: R09) (Cert ID: R10) 16.1 (Cert ID: R11) 16.2 (Cert ID: R12) 16.3 (Cert ID: R13) 16.4 (Cert ID: R14) 16.5 (Cert ID: R15) 16.6 (Cert ID: R16) 16.7 (Cert ID: R17) 16.8 (Cert ID: R18) 16.9 (Cert ID: R19) (Cert ID: R20) (Cert ID: R21) (Cert ID: R22) 17.3 (Cert ID: R23) 17.7 (Cert ID: R24) Latest Version No: CHPL Certification ID: Latest Certification Date: Certification Criteria: R25 November 2017 The following criteria are certified in all versions listed above unless otherwise specified below: (a)(1): Computerized provider order entry

3 (a)(2): Drug-drug, drug-allergy interactions checks (a)(3): Demographics (a)(4): Vital signs, body mass index, and growth Charts (a)(5): Problem list (a)(6): Medication list (a)(7): Medication allergy list (a)(8): Clinical decision support (a)(9): Electronic notes (a)(10): Drug formulary checks (a)(11): Smoking status (a)(12): Image results (a)(13): Family health history (a)(14): Patient list creation (a)(15): Patient-specific education resources (b)(1): Transitions of care - receive, display and incorporate transition of care/referral summaries (b)(2): Transitions of care - create and transmit transition of care/referral summaries (b)(3): Electronic prescribing (b)(4): Clinical information reconciliation (b)(5)(a): Incorporate laboratory tests and values/results (b)(5)(b): Incorporate laboratory tests and values/results* (b)(7): Data portability (c)(1): Clinical quality measures - capture and export (c)(2): Clinical quality measures - import and calculate (c)(3): Clinical quality measures - electronic submission (d)(1): Authentication, access, control, and authorization (d)(2): Auditable events and tamper-resistance (d)(3): Audit report(s) (d)(4): Amendments (d)(5): Automatic log-off (d)(6): Emergency access (d)(7): End-user device encryption (d)(8): Integrity (d)(9): Optional - accounting of disclosures (e)(1): View, download, and transmit to a 3rd party with edge protocol testing (e)(2): Ambulatory setting only -clinical summary (e)(3): Ambulatory setting only - secure messaging (f)(1): Immunization information (f)(2): Transmission to immunization registries (f)(3): Transmission to public health agencies - syndromic surveillance (f)(5): Optional - ambulatory setting only - cancer case information (f)(6): Optional - ambulatory setting only - transmission to cancer registries (g)(2): Automated measure calculation (g)(3): Safety-enhanced design

4 (g)(4): Quality management system * (b)(5)(B) certified in versions and higher only Clinical Quality Measures: The following clinical quality measures are certified in all versions listed above unless otherwise specified below: 1. CMS2 PREVENTIVE CARE AND SCREENING: SCREENING FOR CLINICAL DEPRESSION AND FOLLOW-UP PLAN 2. CMS22 PREVENTIVE CARE AND SCREENING: SCREENING FOR HIGH BLOOD PRESSURE AND FOLLOW-UP DOCUMENTED 3. CMS50 CLOSING THE REFERRAL LOOP: RECEIPT OF SPECIALIST REPORT** 4. CMS52 HIV/AIDS: PNEUMOCYSTIS JIROVECI PNEUMONIA (PCP) PROPHYLAXIS 5. CMS56 FUNCTIONAL STATUS ASSESSMENT FOR HIP REPLACEMENT 6. CMS61 PREVENTIVE CARE AND SCREENING: CHOLESTEROL FASTING LOW DENSITY LIPOPROTEIN (LDL-C) TEST PERFORMED 7. CMS62 HIV/AIDS: MEDICAL VISIT 8. CMS64 PREVENTIVE CARE AND SCREENING: RISK- STRATIFIED CHOLESTEROL FASTING LOW DENSITY LIPOPROTEIN (LDL-C) 9. CMS65 HYPERTENSION: IMPROVEMENT IN BLOOD PRESSURE 10. CMS66 FUNCTIONAL STATUS ASSESSMENT FOR KNEE REPLACEMENT 11. CMS68 DOCUMENTATION OF CURRENT MEDICATIONS IN THE MEDICAL RECORD 12. CMS69 PREVENTIVE CARE AND SCREENING: BODY MASS INDEX (BMI) SCREENING AND FOLLOW-UP 13. CMS74 PRIMARY CARIES PREVENTION INTERVENTION AS OFFERED BY PRIMARY CARE PROVIDERS, INCLUDING DENTISTS 14. CMS75 CHILDREN WHO HAVE DENTAL DECAY OR CAVITIES 15. CMS77 HIV/AIDS: RNA CONTROL FOR PATIENTS WITH HIV 16. CMS82 MATERNAL DEPRESSION SCREENING 17. CMS90 FUNCTIONAL STATUS ASSESSMENT FOR COMPLEX CHRONIC CONDITIONS 18. CMS117 CHILDHOOD IMMUNIZATION STATUS 19. CMS122 DIABETES: HEMOGLOBIN A1C POOR CONTROL 20. CMS123 DIABETES: FOOT EXAM 21. CMS124 CERVICAL CANCER SCREENING 22. CMS125 BREAST CANCER SCREENING 23. CMS126 USE OF APPROPRIATE MEDICATIONS FOR ASTHMA 24. CMS127 PNEUMONIA VACCINATION STATUS FOR OLDER ADULTS 25. CMS128 ANTI-DEPRESSANT MEDICATION MANAGEMENT 26. CMS129 PROSTATE CANCER: AVOIDANCE OF OVERUSE OF BONE SCAN FOR STAGING LOW RISK PROSTATE CANCER PATIENTS 27. CMS130 COLORECTAL CANCER SCREENING 28. CMS131 DIABETES: EYE EXAM 29. CMS132 CATARACTS: COMPLICATIONS WITHIN 30 DAYS FOLLOWING CATARACT SURGERY REQUIRING ADDITIONAL SURGICAL PROCEDURES 30. CMS133 CATARACTS: 20/40 OR BETTER VISUAL ACUITY WITHIN 90 DAYS FOLLOWING CATARACT SURGERY 31. CMS134 DIABETES: URINE PROTEIN SCREENING 32. CMS135 HEART FAILURE (HF): ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITOR OR ANGIOTENSIN RECEPTOR BLOCKER (ARB) THERAPY FOR LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (LVSD) 33. CMS136 ADHD: FOLLOW-UP CARE FOR CHILDREN PRESCRIBED ATTENTION- DEFICIT/HYPERACTIVITY DISORDER (ADHD) MEDICATION

5 34. CMS137 INITIATION AND ENGAGEMENT OF ALCOHOL AND OTHER DRUG DEPENDENCE TREATMENT 35. CMS138 PREVENTIVE CARE AND SCREENING: TOBACCO USE: SCREENING AND CESSATION INTERVENTION 36. CMS139 SCREENING FOR FUTURE FALL RISK 37. CMS140 BREAST CANCER: HORMONAL THERAPY FOR STAGE IC-IIIC ESTROGEN RECEPTOR/PROGESTERONE RECEPTOR (ER/PR) POSITIVE BREAST CANCER 38. CMS141 COLON CANCER: CHEMOTHERAPY FOR AJCC STAGE III COLON CANCER PATIENTS 39. CMS142 DIABETIC RETINOPATHY: COMMUNICATION WITH THE PHYSICIAN MANAGING ONGOING DIABETES CARE 40. CMS143 PRIMARY OPEN ANGLE GLAUCOMA (POAG): OPTIC NERVE EVALUATION 41. CMS144 HEART FAILURE (HF): BETA-BLOCKER THERAPY FOR LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (LVSD) 42. CMS145 CORONARY ARTERY DISEASE (CAD): BETA-BLOCKER THERAPY- PRIOR MYOCARDIAL INFARCTION (MI) OR LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (LVEF <40%) 43. CMS146 APPROPRIATE TESTING FOR CHILDREN WITH PHARYNGITIS 44. CMS147 PREVENTATIVE CARE AND SCREENING: INFLUENZA IMMUNIZATION 45. CMS148 HEMOGLOBIN A1C TEST FOR PEDIATRIC PATIENTS 46. CMS149 DEMENTIA: COGNITIVE ASSESSMENT 47. CMS153 CHLAMYDIA SCREENING FOR WOMEN 48. CMS154 APPROPRIATE TREATMENT FOR CHILDREN WITH UPPER RESPIRATORY INFECTION (URI) 49. CMS155 WEIGHT ASSESSMENT AND COUNSELING FOR NUTRITION AND PHYSICAL ACTIVITY FOR CHILDREN AND ADOLESCENTS 50. CMS156 USE OF HIGH-RISK MEDICATIONS IN THE ELDERLY 51. CMS157 ONCOLOGY: MEDICAL AND RADIATION PAIN INTENSITY QUANTIFIED 52. CMS158 PREGNANT WOMEN THAT HAD HBSAG TESTING 53. CMS159 DEPRESSION REMISSION AT TWELVE MONTHS 54. CMS160 DEPRESSION UTILIZATION OF THE PHQ-9 TOOL 55. CMS161 MAJOR DEPRESSIVE DISORDER (MDD): SUICIDE RISK ASSESSMENT 56. CMS163 DIABETES: LOW DENSITY LIPOPROTEIN (LDL) MANAGEMENT 57. CMS164 ISCHEMIC VASCULAR DISEASE (IVD): USE OF ASPIRIN OR ANOTHER ANTITHROMBOTIC 58. CMS165 CONTROLLING HIGH BLOOD PRESSURE 59. CMS166 USE OF IMAGING STUDIES FOR LOW BACK PAIN 60. CMS167 DIABETIC RETINOPATHY: DOCUMENTATION OF PRESENCE OR ABSENCE OF MACULAR EDEMA AND LEVEL OF SEVERITY OF RETINOPATHY 61. CMS169 BIPOLAR DISORDER AND MAJOR DEPRESSION: APPRAISAL FOR ALCOHOL OR CHEMICAL SUBSTANCE USE 62. CMS177 CHILD AND ADOLESCENT MAJOR DEPRESSIVE DISORDER: SUICIDE RISK ASSESSMENT 63. CMS179 ADE PREVENTION AND MONITORING: WARFARIN TIME IN THERAPEUTIC RANGE 64. CMS182 ISCHEMIC VASCULAR DISEASE (IVD): COMPLETE LIPID PANEL AND LDL CONTROL **CMS50 certified in versions 14.5 and higher only Leveraged Software & Content: athenacommunicator, FDB MedKnowledge, Healthwise Patient Instructions, Surescripts, Network Time Protocol Daemon (ntpd), Epocrates

6 III. Costs and Limitations The section below outlines: (A) Additional types of costs that a user may be required to pay to implement or use the Complete EHR or Health IT Module s capabilities, either to meet meaningful use objectives and measures or to achieve any other use within the scope of the health IT s certification: athenahealth's online implementation service is free for practices with one to six physicians. The onsite implementation fee for larger practices and organizations is based on the number of providers who will be using the athenaclinicals service. All athenaclinicals clients pay a monthly service fee, which covers all features, functionality, and services required to meet Meaningful Use objectives and measures. athenahealth s clients (eligible provider or hospital) would incur no additional costs either to meet meaningful use objectives and measures or to achieve any other use within the scope of the Health IT Module s certification. athenahealth does not charge additional fees for the development or configuration of interfaces or health information exchange integration that are required to meet Meaningful Use requirements. Other health care trading partners and vendors may charge athenahealth clients for the creation, development, and maintenance of interface or health information exchange integration. Clients that elect to use services above and beyond requirements to meet Meaningful Use may pay additional fees. (B) Limitations a user may encounter in the course of implementing and using the Complete EHR or Health IT Module s capabilities, either to meet meaningful use objectives and measures or to achieve any other use within the scope of the health IT s certification. athenahealth s clients (eligible provider or hospital) would incur no limitations either to meet meaningful use objectives and measures or to achieve any other use within the scope of the Health IT Module s certification.